ATS 2019 Virtual Final Program

Chairing: D. Singh, MD, NP, Manchester, United Kingdom S.P. Bhatt, MD, MSPH, Birmingham, AL 201 Laboratory-Based Intermountain Validated Exacerbation (LIVE) Score and Palliative Care Referrals in Patients with Chronic Obstructive Pulmonary Disease/ D.P. Blagev, D.S. Collingridge, S. Rea, R.A. Mularski, S. Zeng, M. Arjomandi, V.G. Press, Murray, UT, p.A2435 202 Influence of Age on the Efficacy of Treatment of Alpha-1 Antitrypsin Deficiency (AATD)/ J.H. Ficker, K.R. Chapman, A.M. Turner, R.A. Sandhaus, M. Wencker, O. Vit, M. Fries, N.G. McElvaney, Nuremberg, Germany, p.A2436 203 Critical Error Rates with the ELLIPTA Inhaler Compared with Other Dry-Powder Inhalers in Patients with COPD: An Open-Label, Low-Intervention Clinical Study/ D. Collier, P. Wielders, J. van der Palen, L. Heyes, D. Midwinter, A. Preece, K. Collison, N. Barnes, R. Sharma, London, United Kingdom, p.A2437 204 Preventing Clinically Important Deterioration (CID) of COPD with Single-inhaler Triple Therapy Fluticasone Furoate/Umeclidinium/Vilanterol: A Prospective Analysis of the IMPACT Trial/ M.K. Han, G.J. Criner, M.T. Dransfield, D.M.G. Halpin, C.E. Jones, S. Kilbride, P. Lange, D.A. Lipson, D.A. Lomas, F.J. Martinez, I. Naya, S.J. Pascoe, R.A. Wise, D. Singh, Ann Arbor, MI, p.A2438 205 Characteristics of Subjects with Exercise-Induced Hypoxemia That Improve Their Exercise Capacity with Oxygen Supplementation/ Y. Perez, I. Vital, R. Calderon, M.A. Campos, Miami, FL, p.A2439 206 Interferon Response to Human Rhinovirus Is Impaired in Alveolar Macrophages but Not Bronchial Epithelial Cells in Chronic Obstructive Pulmonary Disease/ L. Finney, P.S. Fenwick, S. Kemp, E. Bakhsoliani, K.B.R. Belchamber, M.R. Edwards, G.C. Donaldson, L. Donnelly, P. Mallia, S.L. Johnston, J.A. Wedzicha, London, United Kingdom, p.A2440 207 Healthcare Utilization in Smokers with High COPD Assessment Test Score and Preserved Lung Function/ A.M. Guerrero, M.F. Formiga, P. Baghaeishiva, K. Tovar, G. Urdaneta, I.A. Vital, R. Calderon-Candelario, G. Holt, M. Mirsaeidi, M.A. Campos, Miami, FL, p.A2441 208 Feasibility of Bedside Ultrasound to Determine Efficacy of Lung Volume Reduction by Endobronchial Valve Therapy/ A.J. Gangemi, M. Kousha, C. Kim, J. Thomas, L.-Y.H. Criner, M. Gordon, F.C. Cordova, V. Kim, K.V. Shenoy, J.M. Travaline, N. Marchetti, P.B. Desai, G.J. Criner, Philadelphia, PA, p.A2442 209 Aclidinium Bromide Treatment in Patients Receiving Beta-Blockers: Effects on MACE, Moderate/Severe COPD Exacerbations, and Lung Function in Patients with Moderate-to-Very Severe COPD and Cardiovascular Risk Factors (ASCENT-COPD)/ K.R. Chapman, R.A. Wise, B.M. Scirica, D.L. Bhatt, S.Z. Daoud, D. Lythgoe, E. Garcia Gil, Toronto, Canada, p.A2443 210 A 12-52 Week (Variable Length) Randomized Double-Blind Study of Budesonide/Formoterol Fumarate Metered Dose Inhaler (BFF MDI) Compared with Formoterol Fumarate (FF) MDI in COPD (SOPHOS)/ N.A. Hanania, A. Papi, A. Anzueto, F.J. Martinez, K. Rossman, C. Cappelletti, E.A. Duncan, J. Nyberg, P. Dorinsky, Houston, TX, p.A2444 211 Predictors of Comparative Real-World Effectiveness of Triple Therapy Versus Dual Bronchodilation in Frequently Exacerbating Patients with COPD/ M. Kerkhof, J. Voorham, G. Georges, S. Vezzoli, A. Papi, C. Vogelmeier, D. Singh, L.M. Fabbri, J.W.H. Kocks, D.B. Price, Singapore, Singapore, p.A2445 212 Comparative Efficacy of Umeclidinium/Vilanterol, Umeclidinium and Salmeterol in Symptomatic Patients with Chronic Obstructive Pulmonary Disease Free of Inhaled Corticosteroids: The EMAX Trial/ F. Maltais, L.H. Bjermer, E. Kerwin, C. Vogelmeier, M.L. Watkins, L. Tombs, I. Naya, I. Boucot, D.A. Lipson, C. Compton, P. Jones, Quebec, Canada, p.A2446 213 Real-World Use of Rescue Inhaler Sensors, Electronic Symptom Questionnaires and Physical Activity Monitors in COPD Subjects/ A.L. Miller, R.P. Bowler, M. Allinder, S. Jacobson, B. Miller, R. Tal-Singer, N. Locantore, Denver, CO, p.A2447 214 Effect of Home Non-Invasive Ventilation in Moderate-To-Severe COPD with Hypercapnia: A Meta-Analysis of Randomized Controlled Trials/ M. Banifadel, Y. Zayed, M.T.T. Awad, A. Yelangi, M.T. Ghanim, K. Srour, Toledo, OH, p.A2448 215 The Frequency of Exacerbations Treated with Antibiotics, Steroids or Both Differs by GOLD Stage in Patients with COPD in the DYNAGITO Trial/ K.F. Rabe, A. Anzueto, C. Jenkins, A. de la Hoz, F. Voss, J.A. Wedzicha, P.M.A. Calverley, Grosshansdorf, Germany, p.A2449 216 Safety and Tolerability of Four Weeks’ Treatment with a Bradykinin 1 Receptor Antagonist (BI 1026706) in Patients with COPD (GOLD I-III)/ A.-M. Kirsten, D. Singh, F. Pedersen, A. Ludwig-Sengpiel, R. Fuhr, C. Steimle-Goerttler, X. Bai, T. Litzenburger, M. Sarno, A. Gupta, Grosshansdorf, Germany, p.A2450 217 Aclidinium Bromide Added to a Long-Acting B 2 -Agonist +/- Inhaled Corticosteroid: Effects on Exacerbations, Lung Function, and Symptoms in Patients with Chronic Obstructive Pulmonary Disease and Cardiovascular Risk Factors (ASCENT-COPD)/ R.A. Wise, K.R. Chapman, B.M. Scirica, D.L. Bhatt, S.Z. Daoud, S. Zetterstrand, C. Reisner, E. Garcia Gil, Baltimore, MD, p.A2451 218 Impact of Emphysema Heterogeneity on Lung Function in the Setting of Endobronchial Lung Volume Reduction/ A. Majid, G.J. Criner, A. Delage, Boston, MA, p.A2452 219 SABA Use Around COPD Symptom-Based Exacerbations in the London COPD Cohort/ G.C. Donaldson, C. Cabrera, C. Cappelletti, M.A. de Blas, J.A. Wedzicha, London, United Kingdom, p.A2453 220 Prescription of Opioids During the Last 3 Months of Life and Prevalence of Breathlessness and Pain in the Last Week of Life in Severe COPD/ Z. Ahmadi, M.J. Johnson, M.P. Ekstrom, Lund, Sweden, p.A2454 221 Reduction in the Risk of All-Cause Mortality with Fluticasone Furoate/Umeclidinium/Vilanterol Compared to Umeclidinium/Vilanterol in IMPACT Including Previously Missing or Censored Vital Status Data/ D.A. Lipson, G.J. Criner, N. Day, M.T. Dransfield, D.M.G. Halpin, M.K. Han, C.E. Jones, S. Kilbride, P. Lange, D.A. Lomas, P. Manchester, F.J. Martinez, D. Midwinter, A.N. Morris, S.J. Pascoe, D. Singh, R.A. Wise, Philadelphia, PA, p.A7344 ATS 2019 • Dallas, TX SUNDAY • MAY 19 109 SUNDAY AFTERNOON